Home > Riviste > Minerva Endocrinologica > Fascicoli precedenti > Minerva Endocrinologica 2017 December;42(4) > Minerva Endocrinologica 2017 December;42(4):376-84

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Publication history
Estratti
Per citare questo articolo

MINERVA ENDOCRINOLOGICA

Rivista sulle Malattie del Sistema Endocrino


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,383


eTOC

 

REVIEW  


Minerva Endocrinologica 2017 December;42(4):376-84

DOI: 10.23736/S0391-1977.16.02573-6

Copyright © 2016 EDIZIONI MINERVA MEDICA

lingua: Inglese

An update on the metabolic syndrome’s epigenomic risk

Rosa A. PERRICONE 1 , Antonio PIZZUTI 2

1 Department of Cardiological, Nephrological, Anaesthetic and Geriatric Sciences, Faculty of Medicine and Dentistry, “La Sapienza” University of Rome, Rome, Italy; 2 Department of Experimental Medicine, Faculty of Medicine and Dentistry, “La Sapienza” University of Rome, Rome, Italy


PDF  


The primitive genome’s and the individual phenotype’s modifications by epigenetic surveys are crucial to evaluate the metabolic syndrome risk and its prevention. Through the most recent surveys, this analysis aimed to several processes by which the various epigenetic types, who are different from one to another subject, may act on the metabolism key-genes, like that they even indirectly arouse the straight onset of one or more metabolic syndromes: the risk of passing this syndrome to next offspring is more or less high. Through the new later surveys originated from analyses undertaken on animals and experiments on men by in vitro and in vivo, it has been proved how much the epigenetic modifications are affected either by the environmental compounds, often going back to maternal and prenatal nourishment, or by the more or less strong connection to the transcriptional genetic control: this occurs to the stochastic eventuality to pass the metabolic syndrome phenotype’s to the following cohorts. Mainly in an individual observation, these risks evaluation is until now undefined, but it is going in progress. The issues of next new performed surveys can enlighten some interconnection that is following the histonic methylation and the micro-RNA not codifying control role on some gene involved in these metabolic syndromes. This process is variable from one to another subject. All aims to carry out the pharmacological treatment of the primary prevention to the metabolic diseases risk.


KEY WORDS: Metabolism - Epigenomics - Risk factors

inizio pagina

Publication History

Issue published online: September 15, 2017
Article first published online: October 28, 2016
Manuscript accepted: October 21, 2016
Manuscript received: October 13, 2016

Per citare questo articolo

Perricone RA, Pizzuti A. An update on the metabolic syndrome’s epigenomic risk. Minerva Endocrinol 2017;42:376-84. DOI: 10.23736/S0391-1977.16.02573-6

Corresponding author e-mail

rosaanna.perricone@uniroma1.it